Parameter, % change from baseline to week 8 | ACR50 Patients | |||
---|---|---|---|---|
Tocilizumab | Methotrexate | |||
Responders | Non-Responders | Responders | Non-Responders | |
DAS28% mean (CI-95%) | − 54.7 (− 60.1 to −49.3) | −30.0 (− 33.0 to − 27.0) | −46.4 (− 52.1 to − 40.7) | −12.8 (− 15.7 to − 10.1) |
SJC, % mean (CI-95%) | − 78.4 (− 83.8 to − 73.0) | −29.7 (− 37.6 to − 21.7) | −80.7 (− 89.0 to − 72.5) | −22.8 (− 32.1 to − 13.6) |
TJC, % mean (CI-95%) | −76.3 (− 80.7 to − 72.0) | −25.8 (− 34.1 to − 17.5) | −73.6 (− 81.4 to − 65.8) | − 22.1 (− 30.1 to − 14.2) |
VAS Pain, % mean (CI-95%) | −7.7 (− 35.2 to 19.9) | −10.5 (− 28.5 to 7.5) | −40.8 (− 68.3 to − 13.4) | −22.8 (− 36.6 to − 8.9) |